Anaphylaxis
Article Sidebar
Published:
Dec 30, 2013
Keywords:
anaphylaxis, epinephrine, adrenaline
Main Article Content
Abstract
Anaphylaxis was first described by Portier and Richter in 1902. It is defined an acute, potentially fatal, multi-organ system, allergic reaction. The treatment should be started as soon as possible after the first signs occur. It consists mainly of intramuscular administration of epinephrine, introduction venous access and fluid and oxygen therapy as well as constant monitoring.
Downloads
Download data is not yet available.
Article Details
How to Cite
Rapiejko , P., & Lipiec , A. (2013). Anaphylaxis . Alergoprofil, 9(4), 5-10. Retrieved from https://journalsmededu.pl/index.php/alergoprofil/article/view/775
Issue
Section
Article
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Anafilaksja – stanowisko panelu ekspertów Polskiego Towarzystwa Alergologicznego. Kruszewski J. (red.). PTA, Warszawa 2009.
2. Sampson H.A., Munoz-Furlong A., Campbell R.L. et al.: Second symposium on the definition and management of anaphylaxis: summary report – Second National Institute of Allergy and Infection Disease/Food Allergy and Anaphylaxis Network symposium. J. Allergy Clin. Immunol. 2006, 117: 391-397.
3. Simons F.E., Ardusso L.R., Bilo M.B. et al.: World Allergy Organisation Guidelines for the assessment and management of anaphylaxis. WAO Journal 2011, 4: 13-37.
4. Simons F.E., Ardusso L.R., Bilo M.B. et al.: World Allergy Organisation anaphylaxis guidelines: summary. J. Allergy Clin. Immunol. 2011, 127: 587-593.
5. Simons F.E., Ardusso L.R., Bilo M.B. et al.: 2012 Update: World Allergy Organisation Guidelines for the assement and management of anaphylaxis. Curr. Opin. Allergy Clin. Immunol. 2012, 12: 389-399.
6. Panesar S.S., Javad S., de Silva D. et al.: The epidemiology of anaphylaxis in Europe: a systematic review. Allergy 2013, 68: 1353-1361.
7. Tang M.L., Osborne N., Allen K.: Epidemiology of anaphylaxis. Curr. Opin. Allergy Clin. Immunol. 2009, 9: 351-356.
8. van Puijenbroek E.P., Egberts A.C.G., Meyboom R.H.B. et al.: Different risks for NSAID-induced anaphylaxis. Ann. Pharmacother. 2002, 36: 24-29.
9. Hopf Y., Watson M., Williams D.: Adverse drug reaction related admissions to a hospital in Scotland. Pharm. World Sci. 2008, 30: 854-862.
10. Kanny G., Moneret-Vautrin D.A., Flabbee J. et al.: Population study of food allergy in France. J. Allergy Clin. Immunol. 2001, 108: 133-140.
11. Wolbing F., Fishcher J., Köberle M. et al.: About the role and underlying mechanisms of cofactor in anaphylaxis. Allergy 2013, 68(9): 1085-1092.
12. Worm M., Edenharter G., Rueff F. et al.: Symptoms profile and risk factors of anaphylaxis in Central Europe. Allergy 2012, 67: 691-698.
13. Flinterman A.E., Akkerdaas J.H., Knulst A.C. et al.: Hazelnut allergy: from pollen-associated mild allergy to severe anaphylactic reactions. Current opinion in allergy and clinical immunology 2008, 8: 261-265 (za: Canonica W. et al.: A WAO – ARIA – GA2LEN consensus document on molecular – based allergy diagnostics. World Allergy Organization Journal 2013, 6: 17).
14. Braganza S.C., Acworth J.P., Mckinnon D.R.L. et al.: Paediatric emergency department anaphylaxis; different patterns from adults. Arch. Dis. Child. 2006, 91: 159-163.
15. The Diagnosis and Management of Anaphylaxis: An Updated Practice Parameter. J. Allergy Clin. Immunol. 2005, 115: S483-S523.
16. Soar J., Perkin G.D., Abbas G.: Zatrzymanie krążenia: postępowanie w sytuacjach szczególnych; zaburzenia elektrolitowe, zatrucia, tonięcie, przypadkowa hipotermia, hipertermia, astma, anafilaksja, zabiegi kardiochirurgiczne, urazy, ciąża, porażenie prądem. Wytyczne resuscytacji 2010 [online: http:// www.prc.krakow.pl/2010/08.pdf] (Access: 20.12.2013).
17. Lange J., Krauze A.: Adrenalina i jej zastosowanie we wstrząsie anafilaktycznym. Alergoprofil 2007, 3(2): 2-5.
18. President Obama Signs New EpiPen Law To Protect Children with Asthma and Severe Allergies, And Help Their Families To Breathe Easier [online: http://www.whitehouse.gov/ blog/2013/11/13/president-obama-signs-new-epipen-lawprotect-children-asthma-and-severe-allergies-an]opis (Access: 20.12.2013).
2. Sampson H.A., Munoz-Furlong A., Campbell R.L. et al.: Second symposium on the definition and management of anaphylaxis: summary report – Second National Institute of Allergy and Infection Disease/Food Allergy and Anaphylaxis Network symposium. J. Allergy Clin. Immunol. 2006, 117: 391-397.
3. Simons F.E., Ardusso L.R., Bilo M.B. et al.: World Allergy Organisation Guidelines for the assessment and management of anaphylaxis. WAO Journal 2011, 4: 13-37.
4. Simons F.E., Ardusso L.R., Bilo M.B. et al.: World Allergy Organisation anaphylaxis guidelines: summary. J. Allergy Clin. Immunol. 2011, 127: 587-593.
5. Simons F.E., Ardusso L.R., Bilo M.B. et al.: 2012 Update: World Allergy Organisation Guidelines for the assement and management of anaphylaxis. Curr. Opin. Allergy Clin. Immunol. 2012, 12: 389-399.
6. Panesar S.S., Javad S., de Silva D. et al.: The epidemiology of anaphylaxis in Europe: a systematic review. Allergy 2013, 68: 1353-1361.
7. Tang M.L., Osborne N., Allen K.: Epidemiology of anaphylaxis. Curr. Opin. Allergy Clin. Immunol. 2009, 9: 351-356.
8. van Puijenbroek E.P., Egberts A.C.G., Meyboom R.H.B. et al.: Different risks for NSAID-induced anaphylaxis. Ann. Pharmacother. 2002, 36: 24-29.
9. Hopf Y., Watson M., Williams D.: Adverse drug reaction related admissions to a hospital in Scotland. Pharm. World Sci. 2008, 30: 854-862.
10. Kanny G., Moneret-Vautrin D.A., Flabbee J. et al.: Population study of food allergy in France. J. Allergy Clin. Immunol. 2001, 108: 133-140.
11. Wolbing F., Fishcher J., Köberle M. et al.: About the role and underlying mechanisms of cofactor in anaphylaxis. Allergy 2013, 68(9): 1085-1092.
12. Worm M., Edenharter G., Rueff F. et al.: Symptoms profile and risk factors of anaphylaxis in Central Europe. Allergy 2012, 67: 691-698.
13. Flinterman A.E., Akkerdaas J.H., Knulst A.C. et al.: Hazelnut allergy: from pollen-associated mild allergy to severe anaphylactic reactions. Current opinion in allergy and clinical immunology 2008, 8: 261-265 (za: Canonica W. et al.: A WAO – ARIA – GA2LEN consensus document on molecular – based allergy diagnostics. World Allergy Organization Journal 2013, 6: 17).
14. Braganza S.C., Acworth J.P., Mckinnon D.R.L. et al.: Paediatric emergency department anaphylaxis; different patterns from adults. Arch. Dis. Child. 2006, 91: 159-163.
15. The Diagnosis and Management of Anaphylaxis: An Updated Practice Parameter. J. Allergy Clin. Immunol. 2005, 115: S483-S523.
16. Soar J., Perkin G.D., Abbas G.: Zatrzymanie krążenia: postępowanie w sytuacjach szczególnych; zaburzenia elektrolitowe, zatrucia, tonięcie, przypadkowa hipotermia, hipertermia, astma, anafilaksja, zabiegi kardiochirurgiczne, urazy, ciąża, porażenie prądem. Wytyczne resuscytacji 2010 [online: http:// www.prc.krakow.pl/2010/08.pdf] (Access: 20.12.2013).
17. Lange J., Krauze A.: Adrenalina i jej zastosowanie we wstrząsie anafilaktycznym. Alergoprofil 2007, 3(2): 2-5.
18. President Obama Signs New EpiPen Law To Protect Children with Asthma and Severe Allergies, And Help Their Families To Breathe Easier [online: http://www.whitehouse.gov/ blog/2013/11/13/president-obama-signs-new-epipen-lawprotect-children-asthma-and-severe-allergies-an]opis (Access: 20.12.2013).